hb0034
mAbexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Dec 3, 2021 (NCT05064345)
Timeline
Indications
Mechanism of action
- IL36 receptorINHIBITOR
inhibitor - IL1RL2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06716151 | Phase 1 | Dec 10, 2024 | Zhejiang Huahai Pharmaceutical Co., Ltd. |
| NCT06477536 | Phase 2/Phase 3 (Phase 3) | Sep 2, 2024 | Zhejiang Huahai Pharmaceutical Co., Ltd. |
| NCT06231381 | Phase 2 | Feb 29, 2024 | Zhejiang Huahai Pharmaceutical Co., Ltd. |
| NCT05512598 | Phase 1 | Nov 6, 2022 | Shandong University, Zhejiang Huahai Pharmaceutical Co., Ltd. |
| NCT05064345 | Phase 1 | Dec 3, 2021 | Zhejiang Huahai Pharmaceutical Co., Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Zhejiang Huahai Pharmaceutical Co., Ltd. | For profit | 5 | 5 | 3 | 2021 |
| Shandong University | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1